A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Recruiting

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(19 sites)

United States

Neurocrine Clinical Site, Bryant, Arkansas

Neurocrine Clinical Site, Chino, California

Neurocrine Clinical Site, Fountain Valley, California

Neurocrine Clinical Site, Long Beach, California

Neurocrine Clinical Site, Orange, California

Neurocrine Clinical Site, Redlands, California

Neurocrine Clinical Site, San Diego, California

Neurocrine Clinical Site, Bonita Springs, Florida

Neurocrine Clinical Site, Hialeah, Florida

Neurocrine Clinical Site, Miami, Florida

Neurocrine Clinical Site, Orange City, Florida

Neurocrine Clinical Site, Port Charlotte, Florida

Neurocrine Clinical Site, Tampa, Florida

Neurocrine Clinical Site, Marietta, Georgia

Neurocrine Clinical Site, Naperville, Illinois

Neurocrine Clinical Site, Omaha, Nebraska

Neurocrine Clinical Site, Independence, Ohio

Neurocrine Clinical Site, Richmond, Virginia